Compounds > ci 924
Page last updated: 2024-11-07

ci 924

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

CI 924: elevates HDL; structure & RN given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID127627
CHEMBL ID8408
SCHEMBL ID11090691
MeSH IDM0116042

Synonyms (22)

Synonym
5,5'-(1,1'-biphenyl)-2,5-dylbis(oxy)(2,2-dimethylpentanoic acid)
5,5'-[biphenyl-2,5-diylbis(oxy)]bis(2,2-dimethylpentanoic acid)
79520-77-7
ci 924
pentanoic acid, 5,5'-((1,1'-biphenyl)-2,5-diylbis(oxy))bis(2,2-dimethyl-
5,5'-((1,1'-biphenyl)-2,5-diylbis(oxy))bis(2,2-dimethylpentanoic acid)
ci-924
einecs 279-174-7
5,5'-((1,1'-biphenyl)-2,5-diylbis(oxy))bis(2,2-dimethylvaleric) acid
CHEMBL8408
unii-66g4b6td9s
66g4b6td9s ,
SCHEMBL11090691
DTXSID9020162
5-({5-[(4-carboxy-4-methylpentyl)oxy][1,1'-biphenyl]-2-yl}oxy)-2,2-dimethylpentanoic acid
5,5'-[[1,1'-biphenyl]-2,5-diylbis(oxy)]bis[2,2-dimethylpentanoic acid]
5,5'-((1,1'-biphenyl)-2,5-diylbis(oxy))bis-(2,2-dimethyl)pentanoic acid
5-[4-(4-carboxy-4-methylpentoxy)-3-phenylphenoxy]-2,2-dimethylpentanoic acid
5,5'-(1,1'-biphenyl)-2,5-diylbis(oxy)(2,2-dimethylpentanoic acid
PD161041
AKOS040751171
pentanoic acid, 5,5'-[[1,1'-biphenyl]-2,5-diylbis(oxy)]bis[2,2-dimethyl-
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (18)

Assay IDTitleYearJournalArticle
AID172036Hypolipidemic effects(liver weight) in male rats at 12.50 mg/kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
AID172053Hypolipidemic effects(plasma cholesterol) in male rats at 12.50 mg/kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
AID172018Hypolipidemic effects as the ratio of (HDL/LDL) in male rats at dose 25 mg/kg.1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
AID172020Hypolipidemic effects (Low-density lipoprotein (LDL) cholesterol) in male rats at 12.50 mg/kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
AID172039Hypolipidemic effects(liver weight) in male rats at 50 mg/kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
AID172029Hypolipidemic effects (high-density lipoprotein (HDL) cholesterol) in male rats at 25 mg/kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
AID172038Hypolipidemic effects(liver weight) in male rats at 25 mg/kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
AID172055Hypolipidemic effects(plasma cholesterol) in male rats at 25 mg/kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
AID172056Hypolipidemic effects(plasma cholesterol) in male rats at 50 mg/kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
AID172049Hypolipidemic effects(plasma TG) in male rats at 50 mg/kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
AID172017Hypolipidemic effects as the ratio of (HDL/LDL) in male rats at dose 12.5 mg/kg.1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
AID172027Hypolipidemic effects (high-density lipoprotein (HDL) cholesterol) in male rats at 12.50 mg/kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
AID172048Hypolipidemic effects(plasma TG) in male rats at 25 mg/kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
AID172019Hypolipidemic effects as the ratio of (HDL/LDL) in male rats at dose 50 mg/kg.1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
AID172022Hypolipidemic effects (Low-density lipoprotein (LDL) cholesterol) in male rats at 25 mg/kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
AID172046Hypolipidemic effects(plasma TG) in male rats at 12.50 mg/kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
AID172032Hypolipidemic effects (high-density lipoprotein (HDL) cholesterol) in male rats at 50 mg/kg; Compound was screening orally at 50 mg/Kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
AID172024Hypolipidemic effects (Low-density lipoprotein (LDL) cholesterol) in male rats at 50 mg/kg; Compound was screening orally at 50 mg/Kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (25.00)18.7374
1990's2 (25.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's4 (50.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.24

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.24 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.24)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (11.11%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
gemfibrozil
[no description available]		4.4851aromatic etherantilipemic drug
valerates
Valerates: Derivatives of valeric acid, including its salts and esters.		1.9610short-chain fatty acid anion;
straight-chain saturated fatty acid anion		plant metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Bladder Neck Obstruction
[description not available]		02.610
Airflow Obstruction, Chronic
[description not available]		02.610
Pulmonary Disease, Chronic Obstructive
A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.		02.610
Diabetic Feet
[description not available]		02.610
Diabetes Mellitus, Adult-Onset
[description not available]		02.610
Diabetes Mellitus, Type 2
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.		02.610
Diabetic Foot
Common foot problems in persons with DIABETES MELLITUS, caused by any combination of factors such as DIABETIC NEUROPATHIES; PERIPHERAL VASCULAR DISEASES; and INFECTION. With the loss of sensation and poor circulation, injuries and infections often lead to severe foot ulceration, GANGRENE and AMPUTATION.		02.610
Arthritis, Degenerative
[description not available]		02.610
Osteoarthritis
A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans.		02.610
Sarcopenia
Progressive decline in muscle mass due to aging which results in decreased functional capacity of muscles.		02.610
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		01.9810
Apolipoprotein B-100, Familial Defective
[description not available]		03.3611
Carbohydrate Inducible Hyperlipemia
[description not available]		03.3611
Hyperlipoproteinemia Type II
A group of familial disorders characterized by elevated circulating cholesterol contained in either LOW-DENSITY LIPOPROTEINS alone or also in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins).		03.3611
Hyperlipoproteinemia Type IV
A hypertriglyceridemia disorder, often with autosomal dominant inheritance. It is characterized by the persistent elevations of plasma TRIGLYCERIDES, endogenously synthesized and contained predominantly in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins). In contrast, the plasma CHOLESTEROL and PHOSPHOLIPIDS usually remain within normal limits.		03.3611